Molecular Diagnostics Research Group, National Centre for Biomedical Engineering Science, National University of Ireland, Galway, Ireland.
BMC Pregnancy Childbirth. 2010 Mar 10;10:11. doi: 10.1186/1471-2393-10-11.
Activated Protein C Resistance (APCR), a poor anticoagulant response of APC in haemostasis, is the commonest heritable thrombophilia. Adverse outcomes during pregnancy have been linked to APCR. This study determined the frequency of APCR, factor V gene known and novel SNPs and adverse outcomes in a group of pregnant women.
Blood samples collected from 907 pregnant women were tested using the Coatest Classic and Modified functional haematological tests to establish the frequency of APCR. PCR-Restriction Enzyme Analysis (PCR-REA), PCR-DNA probe hybridisation analysis and DNA sequencing were used for molecular screening of known mutations in the factor V gene in subjects determined to have APCR based on the Coatest Classic and/or Modified functional haematological tests. Glycosylase Mediated Polymorphism Detection (GMPD), a SNP screening technique and DNA sequencing, were used to identify SNPs in the factor V gene of 5 APCR subjects.
Sixteen percent of the study group had an APCR phenotype. Factor V Leiden (FVL), FV Cambridge, and haplotype (H) R2 alleles were identified in this group. Thirty-three SNPs; 9 silent SNPs and 24 missense SNPs, of which 20 SNPs were novel, were identified in the 5 APCR subjects. Adverse pregnancy outcomes were found at a frequency of 35% in the group with APCR based on Classic Coatest test only and at 45% in the group with APCR based on the Modified Coatest test. Forty-eight percent of subjects with FVL had adverse outcomes while in the group of subjects with no FVL, adverse outcomes occurred at a frequency of 37%.
Known mutations and novel SNPs in the factor V gene were identified in the study cohort determined to have APCR in pregnancy. Further studies are required to investigate the contribution of these novel SNPs to the APCR phenotype. Adverse outcomes including early pregnancy loss (EPL), preeclampsia (PET) and intrauterine growth restriction (IGUR) were not significantly more frequent in subjects with APCR compared to normal pregnant women however Pregnancy induced hypertension (PIH) was found to be associated with FVL in our study group.
活化蛋白 C 抵抗(APCR)是止血中 APC 抗凝反应不良的常见遗传性血栓形成倾向。妊娠期间的不良结局与 APCR 有关。本研究旨在确定一组孕妇中 APCR、FV 基因已知和新的 SNP 以及不良结局的发生频率。
采集 907 例孕妇的血样,采用 Coatest Classic 和改良功能血液学试验进行检测,以确定 APCR 的频率。对基于 Coatest Classic 和/或改良功能血液学试验确定的 APCR 患者进行 PCR-限制性内切酶分析(PCR-REA)、PCR-DNA 探针杂交分析和 DNA 测序,以对 FV 基因中的已知突变进行分子筛选。糖基化酶介导的多态性检测(GMPD)、SNP 筛选技术和 DNA 测序用于鉴定 5 例 APCR 患者的 FV 基因中的 SNP。
研究组中有 16%的患者存在 APCR 表型。该组中发现了因子 V 莱顿(FVL)、FV 剑桥和单倍型(H)R2 等位基因。在 5 例 APCR 患者中,共鉴定出 33 个 SNP,包括 9 个沉默 SNP 和 24 个错义 SNP,其中 20 个 SNP 是新的。仅基于经典 Coatest 试验检测到的 APCR 组的不良妊娠结局发生率为 35%,而基于改良 Coatest 试验检测到的 APCR 组的不良妊娠结局发生率为 45%。在 FVL 组中,48%的患者有不良结局,而在无 FVL 的组中,不良结局的发生率为 37%。
在妊娠期间被确定为 APCR 的研究队列中,鉴定出了 FV 基因中的已知突变和新的 SNP。需要进一步研究这些新的 SNP 对 APCR 表型的贡献。与正常孕妇相比,不良结局(包括早期妊娠丢失(EPL)、子痫前期(PET)和宫内生长受限(IGUR))在 APCR 患者中并不更为常见,但我们的研究组发现妊娠高血压(PIH)与 FVL 有关。